1. Cystic Fibrosis Drug Maker Nivalis Therapeutics Has $77M IPO

    Cystic Fibrosis Drug Maker Nivalis Therapeutics Has $77M IPO

    Nivalis Therapeutics, a Boulder, CO-based drug company developing a treatment for cystic fibrosis, made its debut on the Nasdaq on Wednesday with a $77 million public offering. Formerly N30 Pharmaceuticals, Nivalis (NASDAQ: NVLS) sold 5.5 million shares, more than it had previously planned, at $14 each. Shares opened the day at $16.50 and climbed to $17.84 within the first hour of trading before dropping to $15.03 at 1 p.m. MT. That gives Nivalis a market capitalization around $219 million.

    Read Full Article
  1. Authors

  2. Categories

    1. Feeds:

      CTA Members Press Releases, CTA Tech Tour, Government & Policy, Tech Workforce & Education
    2. Tags:

      B2B Software, Big Data & Analytics, Business Services Provider, Cloud, Community Organizations, Consumer Software, Development, Energy Tech, Enterprise, Government, Hardware, Health IT, Innovation & Entrepreneurship, Internet of Things, Mobile, Security, Startups, Telecom, Women In Tech